dard chemotherapy have a median survival ranging from Among the 248 patients evaluable for response 125 24 to 36 months with less than 5% of patients surviving at (51%) had a CR and 100 had a PR (40%). The median 10 years. 1-3 The response rates to most conventional duration of progression-free survival (PFS) and overall chemotherapy regimens are usually between 40 and 60%, survival (OS) after transplantation was 23 and 35
134 Table 1 Main characteristics of patients included in the study still needed 13 to determine the role of intensive approach in the treatment of younger myeloma patients. No . 259 Many questions remain to be solved regarding the indi- (20) is the best source of stem cells (BM or PB)?; what is the IgA 50 (19) optimal conditioning regimen?; should the primary goal of Others 20 (8) HDT in MM be the attainment of CR?; what is the role of
Stage at diagnosis post-transplant maintenance therapy? 14 Although it is obvi-I 22 (9) ous that the best way to answer these questions is through II 57 (22) III 180 (69) randomized studies, the availability of registries in which large numbers of patients from many different institutions
Renal insufficiency at diagnosis (serum creatinine Ͼ2 mg/dl) (%) 39 (15) are included may contribute to the clarification of some of ␤2-microglobulin at diagnosis (median) 3.2 mg/dl (22% Ͼ5) these questions. [15] [16] [17] In the present study the outcome of 259 patients from ECOG at diagnosis (%) 0 44 (17) the Spanish Registry who were given HDT followed by
PBSC rescue is analyzed. The specific aims of the study II 69 (27) were: (1) to ascertain the feasibility and toxicity of the pro-III 36 (14) cedure; (2) to evaluate the clinical response achieved after IV 7 (3) transplantation; and (3) to evaluate the factors associated
Time from diagnosis to transplant, months with response post-transplantation, overall survival (OS)
(median with range) 17 and progression or relapse-free survival (PFS).
Time from diagnosis to transplant (Ͻ12 months/Ͼ12 months) (No. of cases) 92/167
Prior chemotherapy regimens (%) were included in this study. Patient characteristics are Nonresponse 25 (10) shown in Table 1 . Median interval from diagnosis to transProgression 25 (10) plantation was 17 months III in 180 cases (69%). Serum creatinine at diagnosis was Busulfan plus cyclophosphamide 27 (10) у2 mg/dl in 39 patients (15%). Osteolytic lesions were
Patients and methods
Cyclophosphamide plus TBI 7 (3) present at diagnosis as minor lytic lesions in 108 patients (42%), as major lesions in 89 patients (34%) and 25 patients (10%) had osteoporosis. Only 37 patients (14%) Recovery of platelets was defined as the first of 7 consecuhad a normal skeletal survey. Transplantation was perfortive days with a platelet count of Ͼ20 × 10 9 /l without premed after the first line of standard treatment in 135 patients vious platelet transfusion. Recovery of more than 1 × 10 9 /l (52%), after a second line of chemotherapy in 61 cases granulocytes and more than 50 × 10 9 /l platelets were also (24%), after a third line in 55 patients (21%) and after four evaluated. or more treatment lines in eight cases (3%). Fifty-six
The criteria for response evaluation for both the standard patients (21%) were transplanted in CR, 153 (59%) in PR, treatment and also for the HDT/autotransplantation regimen 25 patients (10%) with progressive myeloma and the were those defined by Gore et al, 18 with some modifiremaining 25 patients (10%), with non-responding but noncations, summarized as follows: complete response (CR) progressive disease. Criteria of response are defined in the was defined as disappearance of myeloma protein on elecnext section.
tropheresis in both serum and urine, and less than 5% of bone marrow plasma cells. As in the study by Gore et al, Hematopoietic engraftment and response criteria immunofixation was not required for CR consideration. Partial response (PR) required more than 50% reduction Recovery of granulocytes was defined as the first of 3 consecutive days with a granulocyte count of Ͼ0. 19 Curves from difOaks, CA, USA), 5-10 g/kg/day s.c. for 5 days before ferent prognostic groups were compared by means of the starting PBSC collection in 141 cases (54%); (2) high-dose log-rank test. The Cox regression method was used for the cyclophosphamide (HD-CY) (4-7 g/m 2 i.v.), followed by multivariate analysis of factors influencing survival. G-CSF 10 g/kg/day s.c. until the end of leukaphereses, starting the collection when the leukocyte count was Ͼ1 × 10 9 /l, in 65 patients (25%); and (3) the same chemoResults therapy regimen followed by GM-CSF (Leucomax; Sandoz SA/Schering Plough, Basel, Switzerland), 5-8 g/kg/day s.c or i.v. until the end of leukaphereses in 36 patients PBSC mobilization and collection (14%). In 17 patients (7%), PBSC were collected after
The median number of leukaphereses per patient was four priming with chemotherapy alone. The different mobiliz-(range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 18 days (range 6-760), respectively. All patients achieved a plus cyclophosphamide 60 mg/kg × 2 i.v. in 27 (10%) and granulocyte recovery after transplant, whereas five patients cyclophosphamide 60 mg/kg × 2 i.v. plus TBI (8) (9) (10) never reached a platelet count Ͼ50 × 10 9 /l. in seven (3%). Patients were nursed in private rooms according to the available facilities at each institution. AntiTransplant-related toxicity biotics and transfusions were administered as indicated in the transplant unit of each center. 158 patients (61%) Eleven patients (4%) died from procedure-related comreceived G-CSF subcutaneously at doses of 5 g/kg after plications. The causes of toxic death were: sepsis (five stem cell infusion in order to speed granulocyte recovery. patients), interstitial pneumonitis (two cases) hemorrhage (two patients) and respiratory distress and liver venoToxicity occlusive disease (one case each).
Fatal transplant-related toxicity was considered when the patient died from complications directly attributed to HDT Response rate and survival during the first 50 days after transplantation. Deaths secondary to MM progression or other causes not directly Prior to transplantation, 56 patients (21%) were in CR, 153 (59%) were in PR, 25 (10%) had not responded to standard related to conditioning toxicity, were excluded. therapy and 25 (10%) had progressive disease. Eleven patients were not evaluable due to early death. Among the Maintenance therapy 248 patients evaluable for tumoral response after transplant, 125 (51%) were in CR and 100 patients (41%) were in In 114 patients (44%) recombinant alpha interferon (IFN␣2b) was administered as maintenance treatment after PR. The remaining 23 patients showed no response or had Overall response (%) 126 (51) 100 (40) 12 (5) 10 (4) CR = complete response; PR = partial response; Nonresp = nonresponse; Prog = progressive disease.
progressive disease ( Table 2 ). The response rate related to all the 259 patients included in the study was 42% CR, 38% PR and 8% no response. It should be noted that 59 patients (39%) of those transplanted in PR entered CR after HDT. Also, among the 25 cases transplanted with progressive disease, nine (36%) plant, three (12%) entered into CR and 16 (64%) achieved a PR. Median durations of PFS and OS were 23 and 35 months, respectively. The Kaplan-Meier estimated overall survival (OS) and progression-free survival (PFS) at 3 years were 50% and 38%, respectively (Figure 1 ). The 50 patients
Factors associated with CR, EFS and OS posttransplanted with progressive or resistant disease had a sigtransplantation nificantly lower OS and PFS as compared to those transplanted with sensitive disease (P Ͻ 0.05) ( Table 3) Variables associated with higher CR rate after transplan- (Figure 2 ). tation were a favorable response status (CR/PR) at transAfter a median follow-up of 13 months (3-49) posttransplant, 152 patients (60%) are alive and 132 patients plant (P = 0.02), only one line of previous standard therapy remain without disease progression, 37 (28%) in CR and (P = 0.01) and an interval between diagnosis and transplan-95 (71%) in PR. The probability of relapse or progression tation shorter than 12 months (P = 0.01) ( Table 3) . at 3 years was 65%.
Prognostic factors influencing OS at significant level in the univariate analysis were: the number of lines of treatment pretransplant (one vs two or more), the response status pretransplant (CR/PR vs progression/nonresponse) and the use of IFN-␣ as maintenance therapy post-transplant (Table  3) (Figures 2 and 3) . The presence of renal failure at diagnosis had a borderline influence. Concerning PFS, gender (female), favorable response status pretransplant (CR/PR), and maintenance treatment with IFN-␣ post-transplant, were the variables with statistical significant influence (Table 3) (Figures 2 and 3 ). In addition, IgG isotype, a short period from diagnosis to transplant (Ͻ12 months) and the use of TBI as conditioning had a borderline favorable impact on PFS (P Ͼ 0.05 Ͻ 0.1). The method of stem cell mobilization had no significant influence on immediate or long-term results. Multivariate analysis showed that the only independent factors that retained statistical significance were the number of pretransplant induction ( Table 4 ).
137 Table 3 Analysis of prognostic variables Discussion cation strategies with high-dose therapy and autologous stem cell support for patients with MM in recent years. Although randomized trials are the ideal way to evaluate Encouraging results with high-dose therapy followed by autologous stem cell transplantation (ASCT) have been the real impact of these strategies, studies based on large registries are also of interest. [15] [16] [17] reported in selected series of patients with MM. [6] [7] [8] [9] [10] [11] [15] [16] [17] [22] [23] [24] [25] In a controlled randomized study published by the InterThe objectives of our study were to evaluate the feasibility, efficacy and toxicity of autologous PBSC transplangroupe Fraņcais du Myélome, autologous bone marrow transplantation (ABMT) has been shown to be superior to tation in a large series of patients and to analyze prognostic factors of different variables. High-dose chemotherapy with conventional chemotherapy for younger patients. 12 Similar results have been reported on a retrospective case-matched or without TBI, followed by autologous PBSC transplantation, delivered to 259 patients with MM, resulted in low study from the Southwest Oncology Group. 10 Other recent retrospective case-matched analysis, from the EBMT toxicity with only 11 patients (4%) experiencing transplantrelated mortality. This toxicity compares favorably with the Group, comparing allogeneic BMT vs ASCT in MM showed a superior median survival for ASCT due to higher toxicity reported for alloBMT (41%) in the case-matched study mentioned and with other reports including patients transplant-related mortality in the alloBMT group (41 vs 13%), although alloBMT showed a lower relapse rate. 26 autotransplanted at variable times after diagnosis who showed an incidence of toxic deaths ranging from 8 to These promising results have extended the use of intensifi-define CR. Also, a selection bias, that could have influenced patient recruitment cannot be excluded. Nevertheless, 39% of the patients transplanted in PR achieved CR after transplantation. Moreover, within the unfavorable group of the 50 patients transplanted with resistant disease (progressive/nonresponding), 12 (24%) achieved a CR and (23) 46% a PR after transplantation. This finding is in contrast with other more pessimistic observations for such cohorts of patients 27 and as suggested by other authors, 28, 29 indicates that HDT may be helpful as rescue treatment in some MM patients with resistant disease. A wide variety of myeloablative regimens have been used for conditioning in MM before stem-cell infusion.
24,30
Although a significant advantage for regimens including total body irradiation for allogeneic stem-cell transplantation has been suggested, 31 this has not been confirmed in other series, including allogeneic and autologous transplants. 11, 26 Interestingly, although we found no significant differences in terms of response rate, progression-free survival or overall survival with the different regimens used in our series, a favorable trend was detected for those patients conditioned with TBI. In addition, the toxicity was similar regardless of the conditioning used.
Vesole et al 11 have shown that high ␤ 2 -microglobulin of serum ␤ 2 -microglobulin was also associated with longer OS and PFS after autologous stem cell transplantation in other large series of MM patients such as the annual EBMT Regarding the use of post-transplant IFN-␣ as maintea Borderline significance.
nance treatment, recent reports suggest that this agent may be beneficial in prolonging response duration and survival. 16, [32] [33] [34] In contrast, no benefit from IFN-␣ maintenance 24%. [23] [24] [25] Other authors have shown a low incidence of transplant-related mortality ranging from 2 to 4% when a was observed in the French Registry. 17 In our series, both the OS and PFS were significantly longer in the subset of selected series of patients, transplanted immediately after remission induction, were included. 10, [12] [13] [14] [15] [16] [17] The source of patients treated with IFN post-transplant (P Ͻ 0.05). It is difficult to assess the value of IFN just by comparison of stem cell, PBSC in all cases in our study for rescue after high-dose therapy, could have contributed to this low propatients who have received this treatment and those who have not because IFN is started some time after engraftment cedure-related toxicity. In fact, the duration of severe marrow aplasia in our study was shorter than in other series and some kind of bias could have been introduced. It is worthwhile to mention that in our series, the group of supported with autologous bone marrow. 12, 17 In our series a high response rate, with 51% CRs and patients treated with IFN-␣ and the group that received no maintenance, were comparable in terms of engraftment kin-40% PRs among the 248 patients assessable for response, was observed. This occurred even though 120 (48%) of etics and response status post-transplant. More prospective randomized trials are necessary to confirm or refute this patients had previously received у2 lines of induction therapy and 158 (64%) were transplanted у12 months after apparent favorable effect of IFN-␣ on duration of response and survival after transplantation. diagnosis. These results are similar to those observed in other large series. 10, 13, 15, 17 A possible criticism of these favIn summary, our results show that dose-intensive therapy supported by autologous PBSC transplantation is feasible orable results is that a relatively high proportion of patients (21%) were reported as already in CR prior to transplant. therapy in MM patients with low toxicity. With this approach a high CR rate with relatively long survival is This high response rate is probably due to the fact that only electropheresis and not immunofixation was required to observed. In our experience the best results are obtained 
